Topical Erythropoietin Accelerates Wound Closure in Patients with Diabetic Foot Ulcers: A Prospective, Multicenter,...

Area of Science:

• Biomedical research
• Wound healing science
• Endocrinology

Background:

• Diabetic foot ulcers (DFUs) are a severe complication of diabetes mellitus, leading to significant disability.
• Topical erythropoietin (EPO) has shown potential in promoting wound healing.
• Effective treatments for DFUs are crucial to reduce morbidity and amputation rates.

Purpose of the Study:

• To clinically evaluate the efficacy of a novel topical EPO-hydrogel for DFU treatment.
• To compare the healing outcomes of DFUs treated with topical EPO plus standard-of-care (SOC) versus SOC alone.
• To assess the safety and tolerability of topical EPO treatment in DFUs.

Main Methods:

• A randomized controlled trial involving 20 patients with DFUs.
• Participants were randomized to receive either 12 weeks of daily topical EPO with SOC or SOC alone.
• Ulcer closure rates, area reduction, and re-epithelialization were assessed weekly over 12 weeks.

Main Results:

• 75% ulcer closure was achieved in 60% of patients treated with topical EPO and SOC, versus 12.5% in the SOC-alone group.
• DFUs treated with topical EPO and SOC showed a significantly smaller mean area (1.2 cm²) compared to SOC alone (4.2 cm²; p=0.023).
• Faster re-epithelialization was observed in the topical EPO group; no treatment-related adverse events were reported.

Conclusions:

• Topical EPO hydrogel demonstrates significant promise as an effective treatment for promoting diabetic foot ulcer healing.
• The study supports topical EPO as a safe and beneficial adjunct to standard care for DFUs.
• Further research may validate topical EPO for broader clinical application in wound management.